Group 1 - Savara Inc. shares fell over 30% in intraday trading on May 27, 2025, following the FDA's issuance of a Refusal to File letter for its Biologics License Application for Molbreevi, its lead drug candidate for autoimmune PAP [2] - The FDA cited that the submission was "not sufficiently complete" for review, specifically pointing out issues with the CMC section of the application, and Savara was unable to specify what data was missing or why deficiencies were not addressed prior to submission [2] Group 2 - Block & Leviton is investigating Savara Inc. for potential securities law violations and may file an action to recover losses for investors [4] - Investors who have lost money in Savara Inc. investments are encouraged to contact Block & Leviton to learn more about recovery options [5][3] Group 3 - Block & Leviton is recognized as a leading securities class action firm, having recovered billions of dollars for defrauded investors and representing many top institutional investors [7]

Core Viewpoint - Pomerantz LLP is investigating claims of potential securities fraud or unlawful business practices involving Methanex Corporation and its officers or directors [1]. Group 1: Company Performance and Events - On March 9, 2025, Methanex announced an unplanned outage at its 1.8 million tonne methanol plant, Geismar 3, in Louisiana, which occurred in late February [3]. - Following the outage announcement, Methanex's management decided to repair the autothermal reformer (ATR) and estimated a plant startup by early May 2025 [3]. - The stock price of Methanex fell by $5.45 per share, or 12.9%, closing at $36.80 per share on March 10, 2025, after the announcement [4]. Group 2: Legal and Regulatory Context - Pomerantz LLP, a firm known for its work in corporate, securities, and antitrust class litigation, is leading the investigation into Methanex [5]. - The firm has a history of recovering multimillion-dollar damages for victims of securities fraud and corporate misconduct [5].